NaCl 0.9% 100 ml

DRUG2 trials

Sponsors

Oslo University Hospital, General Committee of Teaching Hospitals and Institutes, Egypt

Conditions

Antibiotic ReactionBariatric Surgery CandidateComplication,PostoperativeNon-ST Elevation Myocardial InfarctionWound Infection DeepWound Infection Superficial

Phase 2

Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction

CompletedNCT01491074

Oslo University HospitalNon-ST Elevation Myocardial Infarction

Start: 2011-08-31End: 2014-04-30Updated: 2014-05-19

Unknown Phase

Antibiotic Prophylaxis in Metabolic Bariatric Surgery

Not yet recruitingNCT06510452

General Committee of Teaching Hospitals and Institutes, EgyptAntibiotic Reaction, Bariatric Surgery Candidate, Complication,Postoperative +2

Start: 2024-10-01End: 2026-04-01Target: 3352Updated: 2024-07-31

Related Papers

Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction

Open Heart2018-09-0118 citations

Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction.

2018-06-2926 citations